Evaluating coverage of maternal syphilis screening and treatment within antenatal care to guide service improvements for prevention of congenital syphilis in


Journal

Journal of global health
ISSN: 2047-2986
Titre abrégé: J Glob Health
Pays: Scotland
ID NLM: 101578780

Informations de publication

Date de publication:
Jun 2020
Historique:
entrez: 14 4 2020
pubmed: 14 4 2020
medline: 15 4 2020
Statut: ppublish

Résumé

Countdown to 2030 (CD2030) tracks progress in the 81 countries that account for more than 90% of under-five child deaths and 95% of maternal deaths in the world. In 2017, CD2030 identified syphilis screening and treatment during antenatal care (ANC) as priority indicators for monitoring. Country-reported data in the UNAIDS Global AIDS Monitoring System (GAM) system were used to evaluate four key syphilis indicators from CD2030 countries: (1) maternal syphilis screening and (2) treatment coverage during ANC, (3) syphilis seroprevalence among ANC attendees, and (4) national congenital syphilis (CS) case rates. A cascade analysis for CD2030 countries with coverage data for the number of women attending at least 4 antenatal care visits (ANC4), syphilis testing, seroprevalence and treatment was performed to estimate the number of CS cases that were attributable to missed opportunities for syphilis screening and treatment during antenatal care. Of 81 countries, 52 (64%) reported one or more values for CS indicators into the GAM system during 2016-2017; only 53 (65%) had maternal syphilis testing coverage, 41 (51%) had screening positivity, and 40 (49%) had treatment coverage. CS case rates were reported by 13 (16%) countries. During 2016-2017, four countries reported syphilis screening and treatment coverage of ≥95% consistent with World Health Organization (WHO) targets. Sufficient data were available for 40 (49%) of countries to construct a cascade for data years 2016 and 2017. Syphilis screening and treatment service gaps within ANC4 resulted in an estimated total of 103 648 adverse birth outcomes with 41 858 of these occurring as stillbirths among women attending ANC4 (n = 31 914 408). Women not in ANC4 (n = 25 619 784) contributed an additional 67 348 estimated adverse birth outcomes with 27 198 of these occurring as stillbirths for a total of 69 056 preventable stillbirths attributable to syphilis in these 40 countries. These data and findings can serve as an initial baseline evaluation of antenatal syphilis surveillance and service coverage and can be used to guide improvement of delivery and monitoring of syphilis screening and treatment in ANC for these priority countries.

Sections du résumé

BACKGROUND BACKGROUND
Countdown to 2030 (CD2030) tracks progress in the 81 countries that account for more than 90% of under-five child deaths and 95% of maternal deaths in the world. In 2017, CD2030 identified syphilis screening and treatment during antenatal care (ANC) as priority indicators for monitoring.
METHODS METHODS
Country-reported data in the UNAIDS Global AIDS Monitoring System (GAM) system were used to evaluate four key syphilis indicators from CD2030 countries: (1) maternal syphilis screening and (2) treatment coverage during ANC, (3) syphilis seroprevalence among ANC attendees, and (4) national congenital syphilis (CS) case rates. A cascade analysis for CD2030 countries with coverage data for the number of women attending at least 4 antenatal care visits (ANC4), syphilis testing, seroprevalence and treatment was performed to estimate the number of CS cases that were attributable to missed opportunities for syphilis screening and treatment during antenatal care.
RESULTS RESULTS
Of 81 countries, 52 (64%) reported one or more values for CS indicators into the GAM system during 2016-2017; only 53 (65%) had maternal syphilis testing coverage, 41 (51%) had screening positivity, and 40 (49%) had treatment coverage. CS case rates were reported by 13 (16%) countries. During 2016-2017, four countries reported syphilis screening and treatment coverage of ≥95% consistent with World Health Organization (WHO) targets. Sufficient data were available for 40 (49%) of countries to construct a cascade for data years 2016 and 2017. Syphilis screening and treatment service gaps within ANC4 resulted in an estimated total of 103 648 adverse birth outcomes with 41 858 of these occurring as stillbirths among women attending ANC4 (n = 31 914 408). Women not in ANC4 (n = 25 619 784) contributed an additional 67 348 estimated adverse birth outcomes with 27 198 of these occurring as stillbirths for a total of 69 056 preventable stillbirths attributable to syphilis in these 40 countries.
CONCLUSION CONCLUSIONS
These data and findings can serve as an initial baseline evaluation of antenatal syphilis surveillance and service coverage and can be used to guide improvement of delivery and monitoring of syphilis screening and treatment in ANC for these priority countries.

Identifiants

pubmed: 32280458
doi: 10.7189/jogh.10.010504
pii: jogh-10-010504
pmc: PMC7138526
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

010504

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Informations de copyright

Copyright © 2020 by the Journal of Global Health. All rights reserved.

Déclaration de conflit d'intérêts

Competing interests: The authors completed the ICMJE Unified Competing Interest form (available upon request from the corresponding author), and declare no conflicts of interest.

Références

PLoS One. 2019 Feb 27;14(2):e0211720
pubmed: 30811406
Bull World Health Organ. 2013 Mar 1;91(3):217-26
pubmed: 23476094
Lancet Glob Health. 2019 May;7(5):e655-e663
pubmed: 30910531
PLoS Med. 2017 Dec 27;14(12):e1002473
pubmed: 29281619
Lancet Glob Health. 2016 Nov;4(11):e775-e776
pubmed: 27650656
Lancet Glob Health. 2019 Aug;7(8):e1006-e1008
pubmed: 31303285
Lancet Glob Health. 2016 Feb;4(2):e98-e108
pubmed: 26795602
Int J Gynaecol Obstet. 2015 Jun;130 Suppl 1:S43-50
pubmed: 26054252
Int J Gynaecol Obstet. 2015 Jun;130 Suppl 1:S10-4
pubmed: 25963909
PLoS One. 2014 Jan 29;9(1):e87510
pubmed: 24489931
BMC Public Health. 2011 Apr 13;11 Suppl 3:S9
pubmed: 21501460

Auteurs

Shivika Trivedi (S)

CDC Foundation, Atlanta, Georgia, USA.

Melanie Taylor (M)

World Health Organization, Geneva, Switzerland.
Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.

Mary L Kamb (ML)

Centers for Disease Control and Prevention (CDC), Atlanta, Georgia, USA.

Doris Chou (D)

World Health Organization, Geneva, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH